A Study of LY4005130 in Healthy Participants
Completed · Phase 1 · NCT06690996
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $943,072
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 110
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY4005130 (drug), LY4005130 (drug), Placebo (drug), Placebo (drug)
- Dates
- Started 2024-11-08; completion 2026-04-28
- Results posted
- Not yet
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4005130 gets into the bloodstream and how long it takes the body to eliminate it. Part A for the single-ascending doses (SAD) of the study will last about 12 weeks with 9 visits. Part B for the multiple-ascending doses (MAD) of the study will either last about 16 weeks with 13 visits or 26 weeks with 14 visits not including screening.
From ClinicalTrials.gov, last updated 2026-06-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $943,072 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research LP Dallas $943,072
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.